
OrthoPediatrics (KIDS) Stock Forecast & Price Target
OrthoPediatrics (KIDS) Analyst Ratings
Bulls say
OrthoPediatrics is benefiting from a visible new-product super-cycle, with 3Q26 revenue of $72.7mn rising 18.6% y/y and beating expectations by about 6%, while Trauma & Deformity and Scoliosis both posted strong gains from share takeaways, broader adoption, and new launches. Management’s raised FY26 revenue guide of $270mn-$273mn, alongside reiterated adjusted EBITDA of $25mn and full-year free cash flow breakeven expectations, suggests the company is gaining operating leverage even as near-term EBITDA reflects timing headwinds and investment in growth. Looking ahead, the business appears positioned for durable upside because many launches remain in limited rollout, international growth is still early, and higher-ASP products should improve margins, contracting leverage, and cash generation into 2027 and beyond.
Bears say
OrthoPediatrics is facing a negative fundamental setup because its current and new products may fail to generate sufficient revenue, while share gains and margin expansion could also fall short of expectations. As the company continues to penetrate the pediatric orthopedic TAM, the scope for meaningful growth acceleration appears limited, reducing the odds of a valuation rerating. Competitive pressure from established healthcare firms or smaller differentiated entrants, along with concentration risk, M&A integration risk, and liquidity risk, could further pressure market share, pricing, and quarterly results.
This aggregate rating is based on analysts' research of OrthoPediatrics and is not a guaranteed prediction by Public.com or investment advice.
OrthoPediatrics (KIDS) Analyst Forecast & Price Prediction
Start investing in OrthoPediatrics (KIDS)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About OrthoPediatrics (KIDS) Forecast
OrthoPediatrics (KIDS) Analyst Forecast & Price Prediction
Start investing in OrthoPediatrics (KIDS)
Order type
Buy in
Order amount
Est. shares
0 shares